Outcomes of Enterobacter bloodstream infection in hospitalized children

***Background.*** *Enterobacter spp*. has emerged as a major cause of nosocomial infections in children and adults, and may carry chromosomal *AmpC β*-lactamases that limits the choice of appropriate antibiotics. The antimicrobial treatment strategies for and outcomes of Enterobacter bacteremia in children have not been well described.

***Methods.*** Multicenter, retrospective cohort study of patients ^2^18 years admitted with monomicrobial *Enterobacter spp.* bloodstream infection at The Children\'s Hospital of Philadelphia, Johns Hopkins Children\'s Medical Center and Mayo Clinic Children\'s Hospital. Comprehensive chart review was performed to collect clinical and demographic data on all patients. Antibacterial exposure was recorded daily for 30 days and classified by antimicrobial class and whether combination therapy was used. Descriptive analysis included medians for continuous variables and percentages for categorical data.

***Results.*** From January 2002-December 2012, 471 episodes of bacteremia occurred in 411 children \[Median age: 1.3 years (IQR: 0.3 -- 6.6), male 64%\]. Most children had multiple comorbid conditions and outcomes varied by treatment regimen (Table).

¤New requirement of ventilatory support, vasopressors, intensive care admission or relapse of fever during the first 15 days

¦Isolation of Enterobacter spp. 7 days after onset of bacteremia having documented prior clearance

\* Combination therapy including an aminoglycoside or quinolone plus the main grouping agent

  Baseline characteristics                                                              
  ------------------------------------------------------------------------------------- -----
  ≥3 comorbid medical conditions                                                        88%
  Presence of immunosuppression                                                         38%
  Surgery 1 week prior                                                                  20%
  Presence of central catheter                                                          82%
  Other concomitant infection                                                           26%
  ID consultation during first 15 days                                                  41%
  Catheter removal                                                                      60%
  *Clinical outcomes by definitive therapy grouping (includes 92% of total episodes)*   

  ----------------------- ----------- --------------------- -------------- ---------------- ------------------ --------------- ----------- -------- ---------- --------- ----------
                          **Total**   **3^rd^ cephalosp**   **Cefepime**   **Carbapenem**   **β-lactam inh**   **Quinilone**                                             
                                      Mono 7%               Com\* 18%      Mono 18%         Com\* 9%           Mon 10%         Com\* 13%   Mon 3%   Com\* 7%   Mono 7%   Com\* 2%
  Clinical worsening^¤^   14%         9%                    17%            12%              12%                15%             19%         17%      12%        16%       12%
  Relapse^¦^              5%          9%                    4%             1%               2%                 7%              8%          17%      3%         3%        12%
  30-day mortality        7%          12%                   7%             7%               10%                11%             3%          \-       3%         3%        \-
  ----------------------- ----------- --------------------- -------------- ---------------- ------------------ --------------- ----------- -------- ---------- --------- ----------

***Conclusion.*** *Enterobacter* bacteremia is a severe infection in children. Future studies will compare outcomes by antimicrobial treatment regimen.
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